Central statistical monitoring of investigator-led clinical trials in oncology

被引:13
作者
Buyse, Marc [1 ,2 ,3 ]
Trotta, Laura [3 ]
Saad, Everardo D. [4 ]
Sakamoto, Junichi [5 ,6 ]
机构
[1] Int Drug Dev Inst IDDI, San Francisco, CA 94133 USA
[2] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Hasselt, Belgium
[3] CluePoints, Louvain La Neuve, Belgium
[4] Int Drug Dev Inst IDDI, 30 Ave Prov, B-1340 Ottignies, Belgium
[5] Tokai Cent Hosp, Kakamigahara, Japan
[6] Epidemiol & Clin Res Informat Network ECRIN, Kyoto, Japan
关键词
Investigator-led trials; Central statistical monitoring; Data quality; Trial costs; DATA QUALITY; SYSTEMS; COST;
D O I
10.1007/s10147-020-01726-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Investigator-led clinical trials are pragmatic trials that aim to investigate the benefits and harms of treatments in routine clinical practice. These much-needed trials represent the majority of all trials currently conducted. They are however threatened by the rising costs of clinical research, which are in part due to extensive trial monitoring processes that focus on unimportant details. Risk-based quality management focuses, instead, on "things that really matter". We discuss the role of central statistical monitoring as part of risk-based quality management. We describe the principles of central statistical monitoring, provide examples of its use, and argue that it could help drive down the cost of randomized clinical trials, especially investigator-led trials, whilst improving their quality.
引用
收藏
页码:1207 / 1214
页数:8
相关论文
共 34 条
  • [21] Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review
    Cragg, William J.
    Hurley, Caroline
    Yorke-Edwards, Victoria
    Stenning, Sally P.
    CLINICAL TRIALS, 2021, 18 (02) : 245 - 259
  • [22] Ascertaining Nonfatal Endpoints in Clinical Trials: Central Adjudication Versus Patient Insurance Claims
    Eric L. Eisenstein
    Meredith N. Zozus
    Sharon F. Terry
    Linda Davidson-Ray
    Kevin J. Anstrom
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 1250 - 1257
  • [23] Ascertaining Nonfatal Endpoints in Clinical Trials: Central Adjudication Versus Patient Insurance Claims
    Eisenstein, Eric L.
    Zozus, Meredith N.
    Terry, Sharon F.
    Davidson-Ray, Linda
    Anstrom, Kevin J.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (06) : 1250 - 1257
  • [24] The evolving role of data & safety monitoring boards for real-world clinical trials
    Bunning, Bryan J.
    Hedlin, Haley
    Chen, Jonathan H.
    Ciolino, Jody D.
    Ferstad, Johannes Opsahl
    Fox, Emily
    Garcia, Ariadna
    Go, Alan
    Johari, Ramesh
    Lee, Justin
    Maahs, David M.
    Mahaffey, Kenneth W.
    Opsahl-Ong, Krista
    Perez, Marco
    Rochford, Kaylin
    Scheinker, David
    Spratt, Heidi
    Turakhia, Mintu P.
    Desai, Manisha
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
  • [25] Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies
    Carolina Sotelo-Rodriguez, Diana
    Ruiz-Patino, Alejandro
    Ricaurte, Luisa
    Arrieta, Oscar
    Lucia Zatarain-Barron, Zyanya
    Cardona, Andres F.
    ECANCERMEDICALSCIENCE, 2019, 13
  • [26] Risk-based centralized data monitoring of clinical trials at the time of COVID-19 pandemic
    Afroz, Most Alina
    Schwarber, Grant
    Bhuiyan, Mohammad Alfrad Nobel
    CONTEMPORARY CLINICAL TRIALS, 2021, 104
  • [27] Characteristics of Oncology Clinical Trials Insights From a Systematic Analysis of ClinicalTrials.gov
    Hirsch, Bradford R.
    Califf, Robert M.
    Cheng, Steven K.
    Tasneem, Asba
    Horton, John
    Chiswell, Karen
    Schulman, Kevin A.
    Dilts, David M.
    Abernethy, Amy P.
    JAMA INTERNAL MEDICINE, 2013, 173 (11) : 972 - 979
  • [28] The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial
    Bakobaki, Julie M.
    Rauchenberger, Mary
    Joffe, Nicola
    McCormack, Sheena
    Stenning, Sally
    Meredith, Sarah
    CLINICAL TRIALS, 2012, 9 (02) : 257 - 264
  • [29] Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials
    Saluja, Ronak
    Everest, Louis
    Cheng, Sierra
    Cheung, Matthew
    Chan, Kelvin K. W.
    JAMA ONCOLOGY, 2019, 5 (08) : 1188 - 1194
  • [30] Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting
    Trevor A. Lentz
    Lesley H. Curtis
    Frank W. Rockhold
    David Martin
    Tomas L. G. Andersson
    Carolyn Arias
    Jesse A. Berlin
    Cherie Binns
    Andrea Cook
    Mark Cziraky
    Ricardo Dent
    Manisha Desai
    Andrew Emmett
    Denise Esserman
    Jyothis George
    Stefan Hantel
    Patrick Heagerty
    Adrian F. Hernandez
    Thomas Hucko
    Naeem Khan
    Shun Fu Lee
    Robert LoCasale
    Jack Mardekian
    Debbe McCall
    Keri Monda
    Sharon-Lise Normand
    Jeffrey Riesmeyer
    Matthew Roe
    Lothar Roessig
    Rob Scott
    Harald Siedentop
    Joanne Waldstreicher
    Lin Wang
    Govinda Weerakkody
    Myles Wolf
    Susan S. Ellenberg
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1477 - 1488